Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine

被引:113
作者
Garcia-Hernandez, E.
Gonzalez-Sanchez, J. L.
Andrade-Manzano, A.
Contreras, M. L.
Padilla, S.
Guzman, C. C.
Jimenez, R.
Reyes, L.
Morosoli, G.
Kerde, M. L.
Rosales, R.
机构
[1] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Mol Biol & Biotechnol, Mexico City 04510, DF, Mexico
[2] Inst Mexicano Seguro Social, Hosp Gineco Obstet, Mexico City, DF, Mexico
[3] IMSS, Jefatura Prestaciones, Mexico City, DF, Mexico
[4] Lemery SA CV, Mexico City, DF, Mexico
关键词
papillomavirus; vaccinia virus; MVA; clinical trial; carcinoma in situ;
D O I
10.1038/sj.cgt.7700937
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Human papillomavirus (HPV) is the etiologic agent for cervical cancer. In Mexico, a women dies every 2 h, and since 1990 the statistics have shown that the numbers of deaths are increasing. We conducted a phase II clinical trial to evaluate the potential use of the MVA E2 recombinant vaccinia virus in treating high-grade lesions (CIN 2 and CIN 3) associated with oncogenic papillomavirus. Fifty-four female patients with high degree lesions were treated either with an MVA E2 therapeutic vaccine or with conization. Thirty-four women received the therapeutic vaccine, at a total of 10(7) virus particles per dose injected directly into the uterus once every week over a 6-week period. Twenty control patients were treated with conization. By colposcopy, 19 patients out of 34 showed no lesion, in three patients the lesions were reduced by 85-90%, in eight other lesions had reduced by 60%, and in four more patients, they were reduced by 25%. Histological analysis showed total elimination of high-grade lesions in 20 out of 34 patients after treatment with MVA E2. Eleven patients had a 50% reduction in lesion size. In two other patients, the lesion was reduced to CIN 2 and in one more patient the lesion was reduced to low grade ( CIN 1). All patients developed antibodies against the MVA E2 vaccine, and generated a specific cytotoxic response against papilloma-transformed cells. DNA viral load was significantly reduced in MVA E2-treated patients. Conization eliminated the lesions in 80% of the patients, but patients did not develop cytotoxic activity specific against cancer cells and did not eliminate the papillomavirus. In addition, three patients treated with conization had recurrence of lesions 1 year later. These results show that therapeutic vaccination with MVA E2 proved to be very effective in stimulating the immune system against papillomavirus, and in generating regression of high-grade lesion.
引用
收藏
页码:592 / 597
页数:6
相关论文
共 11 条
[1]  
BINNS MM, 1993, RECOMBINANT POXVIRUS
[2]   Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus [J].
Gutierrez, CMC ;
Tinoco, A ;
Navarro, T ;
Contreras, ML ;
Cortes, RR ;
Calzado, P ;
Reyes, L ;
Posternak, R ;
Morosoli, G ;
Verde, ML ;
Rosales, R .
HUMAN GENE THERAPY, 2004, 15 (05) :421-431
[3]  
Gutierrez CMC, 2002, HUM GENE THER, V13, P1127
[4]   Development of a DNA-MVA/HIVA vaccine for Kenya [J].
Hanke, T ;
McMichael, AJ ;
Mwau, M ;
Wee, EGT ;
Ceberej, I ;
Patel, S ;
Sutton, J ;
Tomlinson, M ;
Samuel, RV .
VACCINE, 2002, 20 (15) :1995-1998
[5]   Human papillomavirus vaccines and prevention of cervical cancer [J].
Jansen, KU ;
Shaw, AR .
ANNUAL REVIEW OF MEDICINE, 2004, 55 :319-331
[6]   ESTIMATES OF THE WORLDWIDE FREQUENCY OF 16 MAJOR CANCERS IN 1980 [J].
PARKIN, DM ;
LAARA, E ;
MUIR, CS .
INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (02) :184-197
[7]   MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis [J].
Roque-Reséndiz, JL ;
Rosales, R ;
Herion, P .
PARASITOLOGY, 2004, 128 :397-405
[8]   A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity [J].
Rosales, C ;
Graham, VV ;
Rosas, GA ;
Merchant, H ;
Rosales, R .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (07) :347-360
[9]   A RECOMBINANT VECTOR DERIVED FROM THE HOST RANGE-RESTRICTED AND HIGHLY ATTENUATED MVA STRAIN OF VACCINIA VIRUS STIMULATES PROTECTIVE IMMUNITY IN MICE TO INFLUENZA-VIRUS [J].
SUTTER, G ;
WYATT, LS ;
FOLEY, PL ;
BENNINK, JR ;
MOSS, B .
VACCINE, 1994, 12 (11) :1032-1040
[10]  
Valadez G., 2000, CANCER, V88, P1650